Abstract
Purpose
The dawn of the state-of-the-art methods of cancer treatments, nano-based delivery systems, has dispensed with the mainstream chemotherapy for being inadequate in yielding productive results and the numerous reported side effects. The popularity of this complementary approach in the course of the last two decades has been primarily attributed to its capacity to elevate the therapeutic index of anticancer drugs as well as removing the impassable delivery barriers in solid tumors with the minimal damage to the normal tissues.
Methods
The PubMed database was consulted to compile this review.
Results
A wide range of minuscule organic and inorganic nanomaterials, with dimensions not exceeding hundred nanometers, has led to hope for cancer therapy to flare-up once again due to possessing a number of exclusive traits for passive and active tumor targeting, some of which are EPR effect, high interstitial pressure of tumor, overexpressed receptors and angiogenesis. Although a limited number of liposomal and polymer-based therapeutic nanoparticles have gained applicability, a vast number of nanoparticles are still being trailed in order to be fully developed.
Conclusions
This study provides an overview of the advantages/disadvantages of nanocarriers for cancer drug delivery.
Similar content being viewed by others
References
Jain RK, Stylianopoulos T (2010) Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7(11):653–664. doi:10.1038/nrclinonc.2010.139
Feng L, Mumper RJ (2013) A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett 334(2):157–175. doi:10.1016/j.canlet.2012.07.006
Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC (2014) Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 66:2–25. doi:10.1016/j.addr.2013.11.009
Li Y, Wang J, Wientjes MG, Au JL (2012) Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev 64(1):29–39. doi:10.1016/j.addr.2011.04.006
Dong X, Mumper RJ (2010) Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond) 5(4):597–615. doi:10.2217/nnm.10.35
Dawidczyk CM, Kim C, Park JH, Russell LM, Lee KH, Pomper MG, Searson PC (2014) State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release 187:133–144. doi:10.1016/j.jconrel.2014.05.036
Hollis CP, Weiss HL, Leggas M, Evers BM, Gemeinhart RA, Li T (2013) Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. J Control Release 172(1):12–21. doi:10.1016/j.jconrel.2013.06.039
Rofstad EK, Ruud EB, Mathiesen B, Galappathi K (2010) Associations between radiocurability and interstitial fluid pressure in human tumor xenografts without hypoxic tissue. Clin Cancer Res 16(3):936–945. doi:10.1158/1078-0432.ccr-09-2718
Nichols JW, Bae YH (2012) Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today 7(6):606–618. doi:10.1016/j.nantod.2012.10.010
Maeda H, Sawa T, Konno T (2001) Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74(1–3):47–61
Kim R, Emi M, Tanabe K (2007) Cancer immunoediting from immune surveillance to immune escape. Immunology 121(1):1–14. doi:10.1111/j.1365-2567.2007.02587.x
Egeblad M, Nakasone ES, Werb Z (2010) Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 18(6):884–901. doi:10.1016/j.devcel.2010.05.012
Choi YP, Shim HS, Gao MQ, Kang S, Cho NH (2011) Molecular portraits of intratumoral heterogeneity in human ovarian cancer. Cancer Lett 307(1):62–71. doi:10.1016/j.canlet.2011.03.018
Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58–62. doi:10.1126/science.1104819
Nichols JW, Bae YH (2014) EPR: evidence and fallacy. J Control Release 190:451–464. doi:10.1016/j.jconrel.2014.03.057
Bae YH, Park K (2011) Targeted drug delivery to tumors: myths, reality and possibility. J Control Release 153(3):198–205. doi:10.1016/j.jconrel.2011.06.001
Kumar A, Chen F, Mozhi A, Zhang X, Zhao Y, Xue X, Hao Y, Zhang X, Wang PC, Liang XJ (2013) Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation. Nanoscale 5(18):8307–8325. doi:10.1039/c3nr01525d
Theek B, Gremse F, Kunjachan S, Fokong S, Pola R, Pechar M, Deckers R, Storm G, Ehling J, Kiessling F, Lammers T (2014) Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging. J Control Release 182:83–89. doi:10.1016/j.jconrel.2014.03.007
Rawat M, Singh D, Saraf S, Saraf S (2006) Nanocarriers: promising vehicle for bioactive drugs. Biol Pharm Bull 29(9):1790–1798
Benhabbour SR, Luft JC, Kim D, Jain A, Wadhwa S, Parrott MC, Liu R, DeSimone JM, Mumper RJ (2012) In vitro and in vivo assessment of targeting lipid-based nanoparticles to the epidermal growth factor-receptor (EGFR) using a novel Heptameric ZEGFR domain. J Control Release 158(1):63–71. doi:10.1016/j.jconrel.2011.10.013
Maeda H, Nakamura H, Fang J (2013) The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 65(1):71–79. doi:10.1016/j.addr.2012.10.002
Rabanel JM, Hildgen P, Banquy X (2014) Assessment of PEG on polymeric particles surface, a key step in drug carrier translation. J Control Release 185:71–87. doi:10.1016/j.jconrel.2014.04.017
Jia F, Liu X, Li L, Mallapragada S, Narasimhan B, Wang Q (2013) Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents. J Control Release 172(3):1020–1034. doi:10.1016/j.jconrel.2013.10.012
Danhier F, Feron O, Preat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148(2):135–146. doi:10.1016/j.jconrel.2010.08.027
Arias JL (2011) Drug targeting strategies in cancer treatment: an overview. Mini Rev Med Chem 11(1):1–17
Maeda H (2012) Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Controll Release 164(2):138–144. doi:10.1016/j.jconrel.2012.04.038
Lammers T, Kiessling F, Hennink WE, Storm G (2012) Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 161(2):175–187. doi:10.1016/j.jconrel.2011.09.063
Kopecek J (2013) Polymer-drug conjugates: origins, progress to date and future directions. Adv Drug Deliv Rev 65(1):49–59. doi:10.1016/j.addr.2012.10.014
Zhang Y, Huang Y, Li S (2014) Polymeric micelles: nanocarriers for cancer-targeted drug delivery. AAPS PharmSciTech 15(4):862–871. doi:10.1208/s12249-014-0113-z
Lu Y, Park K (2013) Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int J Pharm 453(1):198–214. doi:10.1016/j.ijpharm.2012.08.042
Perez-Herrero E, Fernandez-Medarde A (2015) Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 93:52–79. doi:10.1016/j.ejpb.2015.03.018
Oerlemans C, Bult W, Bos M, Storm G, Nijsen JF, Hennink WE (2010) Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res 27(12):2569–2589. doi:10.1007/s11095-010-0233-4
Deng C, Jiang Y, Cheng R, Meng F, Zhong Z (2012) Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: promises, progress and prospects. Nano Today 7(5):467–480. doi:10.1016/j.nantod.2012.08.005
Yang Y, Pan D, Luo K, Li L, Gu Z (2013) Biodegradable and amphiphilic block copolymer-doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy. Biomaterials 34(33):8430–8443. doi:10.1016/j.biomaterials.2013.07.037
Loh XJ, del Barrio J, Toh PP, Lee TC, Jiao D, Rauwald U, Appel EA, Scherman OA (2012) Triply triggered doxorubicin release from supramolecular nanocontainers. Biomacromolecules 13(1):84–91. doi:10.1021/bm201588m
Yan F, Li L, Deng Z, Jin Q, Chen J, Yang W, Yeh CK, Wu J, Shandas R, Liu X, Zheng H (2013) Paclitaxel-liposome-microbubble complexes as ultrasound-triggered therapeutic drug delivery carriers. J Control Release 166(3):246–255. doi:10.1016/j.jconrel.2012.12.025
Luo Z, Hu Y, Cai K, Ding X, Zhang Q, Li M, Ma X, Zhang B, Zeng Y, Li P, Li J, Liu J, Zhao Y (2014) Intracellular redox-activated anticancer drug delivery by functionalized hollow mesoporous silica nanoreservoirs with tumor specificity. Biomaterials 35(27):7951–7962. doi:10.1016/j.biomaterials.2014.05.058
Liu J, Huang Y, Kumar A, Tan A, Jin S, Mozhi A, Liang XJ (2014) pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol Adv 32(4):693–710. doi:10.1016/j.biotechadv.2013.11.009
Felber AE, Dufresne MH, Leroux JC (2012) pH-sensitive vesicles, polymeric micelles, and nanospheres prepared with polycarboxylates. Adv Drug Deliv Rev 64(11):979–992. doi:10.1016/j.addr.2011.09.006
Bae YM, Park YI, Nam SH, Kim JH, Lee K, Kim HM, Yoo B, Choi JS, Lee KT, Hyeon T, Suh YD (2012) Endocytosis, intracellular transport, and exocytosis of lanthanide-doped upconverting nanoparticles in single living cells. Biomaterials 33(35):9080–9086. doi:10.1016/j.biomaterials.2012.08.039
Costantino L, Boraschi D (2012) Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents? Drug Discov Today 17(7–8):367–378. doi:10.1016/j.drudis.2011.10.028
Ulbrich K, Subr V (2004) Polymeric anticancer drugs with pH-controlled activation. Adv Drug Deliv Rev 56(7):1023–1050. doi:10.1016/j.addr.2003.10.040
Tan ML, Choong PF, Dass CR (2010) Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides 31(1):184–193. doi:10.1016/j.peptides.2009.10.002
Locatelli E, Comes Franchini M (2012) Biodegradable PLGA-b-PEG polymeric nanoparticles: synthesis, properties, and nanomedical applications as drug delivery system. J Nanopart Res 14(12):1–17. doi:10.1007/s11051-012-1316-4
Lai P, Daear W, Lobenberg R, Prenner EJ (2014) Overview of the preparation of organic polymeric nanoparticles for drug delivery based on gelatine, chitosan, poly(d, l-lactide-co-glycolic acid) and polyalkylcyanoacrylate. Colloids Surf B Biointerfaces 118:154–163. doi:10.1016/j.colsurfb.2014.03.017
Fernandez-Fernandez A, Manchanda R, McGoron AJ (2011) Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms. Appl Biochem Biotechnol 165(7–8):1628–1651. doi:10.1007/s12010-011-9383-z
Wang A, Gu F, Farokhzad O (2009) Nanoparticles for Cancer Diagnosis and Therapy. In: Webster TJ (ed) Safety of Nanoparticles. Nanostructure Science and Technology. Springer New York, pp 209–235. doi:10.1007/978-0-387-78608-7_10
Herrero EP, Alonso MJ, Csaba N (2012) Polymer-based oral peptide nanomedicines. Ther Deliv 3(5):657–668
Allen TM, Cullis PR (2013) Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 65(1):36–48. doi:10.1016/j.addr.2012.09.037
Sen K, Mandal M (2013) Second generation liposomal cancer therapeutics: transition from laboratory to clinic. Int J Pharm 448(1):28–43. doi:10.1016/j.ijpharm.2013.03.006
Fan Y, Zhang Q (2013) Development of liposomal formulations: from concept to clinical investigations. Asian J Pharm Sci 8(2):81–87. doi:10.1016/j.ajps.2013.07.010
Szebeni J (2005) Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216(2–3):106–121. doi:10.1016/j.tox.2005.07.023
Cosco D, Paolino D, Cilurzo F, Casale F, Fresta M (2012) Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases. Int J Pharm 422(1–2):229–237. doi:10.1016/j.ijpharm.2011.10.056
Brown S, Khan DR (2012) The treatment of breast cancer using liposome technology. J Drug Deliv 2012:212965. doi:10.1155/2012/212965
Infante JR, Keedy VL, Jones SF, Zamboni WC, Chan E, Bendell JC, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg ML, Burris HA 3rd (2012) Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemother Pharmacol 70(5):699–705. doi:10.1007/s00280-012-1960-5
Blanco E, Hsiao A, Mann AP, Landry MG, Meric-Bernstam F, Ferrari M (2011) Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci 102(7):1247–1252. doi:10.1111/j.1349-7006.2011.01941.x
Kono K, Ozawa T, Yoshida T, Ozaki F, Ishizaka Y, Maruyama K, Kojima C, Harada A, Aoshima S (2010) Highly temperature-sensitive liposomes based on a thermosensitive block copolymer for tumor-specific chemotherapy. Biomaterials 31(27):7096–7105. doi:10.1016/j.biomaterials.2010.05.045
Calderon M, Quadir MA, Strumia M, Haag R (2010) Functional dendritic polymer architectures as stimuli-responsive nanocarriers. Biochimie 92(9):1242–1251. doi:10.1016/j.biochi.2010.02.017
Fleige E, Quadir MA, Haag R (2012) Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv Drug Deliv Rev 64(9):866–884. doi:10.1016/j.addr.2012.01.020
Park SM, Kim MS, Park SJ, Park ES, Choi KS, Kim YS, Kim HR (2013) Novel temperature-triggered liposome with high stability: formulation, in vitro evaluation, and in vivo study combined with high-intensity focused ultrasound (HIFU). J Control Release 170(3):373–379. doi:10.1016/j.jconrel.2013.06.003
Huwyler J, Drewe J, Krahenbuhl S (2008) Tumor targeting using liposomal antineoplastic drugs. Int J Nanomedicine 3(1):21–29
Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks JD, Kirpotin DB (2010) Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release 141(1):13–21. doi:10.1016/j.jconrel.2009.08.006
Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2(10):750–763. doi:10.1038/nrc903
Torchilin VP (2007) Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 9(2):E128–E147. doi:10.1208/aapsj0902015
Panyam J, Dali MM, Sahoo SK, Ma W, Chakravarthi SS, Amidon GL, Levy RJ, Labhasetwar V (2003) Polymer degradation and in vitro release of a model protein from poly(D, L-lactide-co-glycolide) nano- and microparticles. J Control Release 92(1–2):173–187
Arleth L, Ashok B, Onyuksel H, Thiyagarajan P, Jacob J, Hjelm RP (2005) Detailed structure of hairy mixed micelles formed by phosphatidylcholine and PEGylated phospholipids in aqueous media. Langmuir 21(8):3279–3290. doi:10.1021/la047588y
Muqbil I, Masood A, Sarkar FH, Mohammad RM, Azmi AS (2011) Progress in nanotechnology based approaches to enhance the potential of chemopreventive agents. Cancers (Basel) 3(1):428–445. doi:10.3390/cancers3010428
Das S, Chaudhury A (2011) Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 12(1):62–76. doi:10.1208/s12249-010-9563-0
Rostami E, Kashanian S, Azandaryani AH, Faramarzi H, Dolatabadi JE, Omidfar K (2014) Drug targeting using solid lipid nanoparticles. Chem Phys Lipids. doi:10.1016/j.chemphyslip.2014.03.006
Mehnert W, Mäder K (2012) Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 64:83–101. doi:10.1016/j.addr.2012.09.021
Kakde D, Jain D, Shrivastava V, Kakde R, Patil A (2011) Cancer therapeutics-opportunities, challenges and advances in drug delivery. J Appl Pharm Sci 1(9):1–10
Wissing SA, Kayser O, Muller RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56(9):1257–1272. doi:10.1016/j.addr.2003.12.002
Liu D, Liu Z, Wang L, Zhang C, Zhang N (2011) Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces 85(2):262–269. doi:10.1016/j.colsurfb.2011.02.038
Sainsbury F, Zeng B, Middelberg APJ (2014) Towards designer nanoemulsions for precision delivery of therapeutics. Cur Opin Chem Eng 4:11–17. doi:10.1016/j.coche.2013.12.007
Mandal B, Bhattacharjee H, Mittal N, Sah H, Balabathula P, Thoma LA, Wood GC (2013) Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform. Nanomedicine 9(4):474–491. doi:10.1016/j.nano.2012.11.010
Hadinoto K, Sundaresan A, Cheow WS (2013) Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm 85(3):427–443. doi:10.1016/j.ejpb.2013.07.002
Pensado A, Seijo B, Sanchez A (2014) Current strategies for DNA therapy based on lipid nanocarriers. Expert Opin Drug Deliv 11(11):1721–1731. doi:10.1517/17425247.2014.935337
Narvekar M, Xue HY, Wong HL (2012) A novel hybrid delivery system: polymer-oil nanostructured carrier for controlled delivery of highly lipophilic drug all-trans-retinoic acid (ATRA). Int J Pharm 436(1–2):721–731. doi:10.1016/j.ijpharm.2012.07.042
Chatterjee DK, Wolfe T, Lee J, Brown AP, Singh PK, Bhattarai SR, Diagaradjane P, Krishnan S (2013) Convergence of nanotechnology with radiation therapy-insights and implications for clinical translation. Transl Cancer Res 2(4):256–268. doi:10.3978/j.issn.2218-676X.2013.08.10
Jain AK, Das M, Swarnakar NK, Jain S (2011) Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics. Crit Rev Ther Drug Carrier Syst 28(1):1–45
Deshpande PP, Biswas S, Torchilin VP (2013) Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond) 8(9):1509–1528. doi:10.2217/nnm.13.118
Byrne JD, Betancourt T, Brannon-Peppas L (2008) Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60(15):1615–1626. doi:10.1016/j.addr.2008.08.005
Yu MK, Park J, Jon S (2012) Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2(1):3–44. doi:10.7150/thno.3463
Sanna V, Pala N, Sechi M (2014) Targeted therapy using nanotechnology: focus on cancer. Int J Nanomedicine 9:467–483. doi:10.2147/ijn.s36654
McCarthy JR, Bhaumik J, Karver MR, Sibel Erdem S, Weissleder R (2010) Targeted nanoagents for the detection of cancers. Mol Oncol 4(6):511–528. doi:10.1016/j.molonc.2010.08.003
Zwicke GL, Mansoori GA, Jeffery CJ (2012) Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev. doi:10.3402/nano.v3i0.18496
Low PS, Antony AC (2004) Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv Drug Deliv Rev 56(8):1055–1058. doi:10.1016/j.addr.2004.02.003
Liu Y, Li K, Pan J, Liu B, Feng SS (2010) Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials 31(2):330–338. doi:10.1016/j.biomaterials.2009.09.036
Pirollo KF, Chang EH (2008) Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends Biotechnol 26(10):552–558. doi:10.1016/j.tibtech.2008.06.007
Hussain S, Pluckthun A, Allen TM, Zangemeister-Wittke U (2007) Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol Cancer Ther 6(11):3019–3027. doi:10.1158/1535-7163.mct-07-0615
Ahn HK, Jung M, Sym SJ, Shin DB, Kang SM, Kyung SY, Park JW, Jeong SH, Cho EK (2014) A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 74(2):277–282. doi:10.1007/s00280-014-2498-5
Matsumura Y (2011) Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv Drug Deliv Rev 63(3):184–192. doi:10.1016/j.addr.2010.05.008
Hamaguchi T, Doi T, Eguchi-Nakajima T, Kato K, Yamada Y, Shimada Y, Fuse N, Ohtsu A, Matsumoto S, Takanashi M, Matsumura Y (2010) Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin Cancer Res 16(20):5058–5066. doi:10.1158/1078-0432.ccr-10-0387
Lee SW, Yun MH, Jeong SW, In CH, Kim JY, Seo MH, Pai CM, Kim SO (2011) Development of docetaxel-loaded intravenous formulation, Nanoxel-PM using polymer-based delivery system. J Control Release 155(2):262–271. doi:10.1016/j.jconrel.2011.06.012
Liu D, He C, Wang AZ, Lin W (2013) Application of liposomal technologies for delivery of platinum analogs in oncology. Int J Nanomedicine 8:3309–3319. doi:10.2147/ijn.s38354
Harrington KJ, Lewanski CR, Northcote AD, Whittaker J, Wellbank H, Vile RG, Peters AM, Stewart JS (2001) Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol 12(4):493–496
Schutz CA, Juillerat-Jeanneret L, Mueller H, Lynch I, Riediker M (2013) Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine (Lond) 8(3):449–467. doi:10.2217/nnm.13.8
Tippayamontri T, Kotb R, Paquette B, Sanche L (2013) Efficacy of cisplatin and Lipoplatin in combined treatment with radiation of a colorectal tumor in nude mouse. Anticancer Res 33(8):3005–3014
Stathopoulos GP, Boulikas T (2012) Lipoplatin formulation review article. J Drug Deliv 2012:581363. doi:10.1155/2012/581363
Zheng S, Chang S, Lu J, Chen Z, Xie L, Nie Y, He B, Zou S, Gu Z (2011) Characterization of 9-nitrocamptothecin liposomes: anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo. PLoS One 6(6):e21064. doi:10.1371/journal.pone.0021064
Tippayamontri T, Kotb R, Paquette B, Sanche L (2011) Cellular uptake and cytoplasm/DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116. Invest New Drugs 29(6):1321–1327. doi:10.1007/s10637-010-9494-3
Koudelka S, Turanek J (2012) Liposomal paclitaxel formulations. J Control Release 163(3):322–334. doi:10.1016/j.jconrel.2012.09.006
Duncan R, Gaspar R (2011) Nanomedicine(s) under the microscope. Mol Pharm 8(6):2101–2141. doi:10.1021/mp200394t
Wittgen BP, Kunst PW, Perkins WR, Lee JK, Postmus PE (2006) Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin. J Aerosol Med 19(3):385–391. doi:10.1089/jam.2006.19.385
Duffaud F, Borner M, Chollet P, Vermorken JB, Bloch J, Degardin M, Rolland F, Dittrich C, Baron B, Lacombe D, Fumoleau P (2004) Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study. Eur J Cancer 40(18):2748–2752. doi:10.1016/j.ejca.2004.08.024
Gelmon K, Hirte H, Fisher B, Walsh W, Ptaszynski M, Hamilton M, Onetto N, Eisenhauer E (2004) A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers. Invest New Drugs 22(3):263–275. doi:10.1023/B:DRUG.0000026252.86842.e2
Booser DJ, Esteva FJ, Rivera E, Valero V, Esparza-Guerra L, Priebe W, Hortobagyi GN (2002) Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother Pharmacol 50(1):6–8. doi:10.1007/s00280-002-0464-0
Slingerland M, Guchelaar HJ, Gelderblom H (2012) Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today 17(3–4):160–166. doi:10.1016/j.drudis.2011.09.015
Deeken JF, Slack R, Weiss GJ, Ramanathan RK, Pishvaian MJ, Hwang J, Lewandowski K, Subramaniam D, He AR, Cotarla I, Rahman A, Marshall JL (2013) A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol 71(3):627–633. doi:10.1007/s00280-012-2048-y
Egusquiaguirre SP, Igartua M, Hernandez RM, Pedraz JL (2012) Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin Transl Oncol 14(2):83–93. doi:10.1007/s12094-012-0766-6
Pal A, Khan S, Wang YF, Kamath N, Sarkar AK, Ahmad A, Sheikh S, Ali S, Carbonaro D, Zhang A, Ahmad I (2005) Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. Anticancer Res 25(1A):331–341
Zamboni WC, Ramalingam S, Friedland DM, Edwards RP, Stoller RG, Strychor S, Maruca L, Zamboni BA, Belani CP, Ramanathan RK (2009) Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clin Cancer Res 15(4):1466–1472. doi:10.1158/1078-0432.ccr-08-1405
Neville ME, Boni LT, Pflug LE, Popescu MC, Robb RJ (2000) Biopharmaceutics of liposomal interleukin 2, oncolipin. Cytokine 12(11):1691–1701. doi:10.1006/cyto.2000.0769
Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, Tompsett D, Troiano G, Van Geen Hoven T, Wright J, LoRusso P, Kantoff PW, Bander NH, Sweeney C, Farokhzad OC, Langer R, Zale S (2012) Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 4(128):128ra139. doi:10.1126/scitranslmed.3003651
Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, Hilker C, Deuster S, Herrmann R, Rochlitz C (2012) Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol 13(12):1234–1241. doi:10.1016/s1470-2045(12)70476-x
Wickham T, Futch K (2012) A phase I study of MM-302, a HER2-targeted liposomal doxorubicin. Patients with advanced, HER2-positive breast cancer. Cancer Res 72:P5–P18
Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, Okuwa M, Matsumoto S, Miyata Y, Ohkura H, Chin K, Baba S, Yamao T, Kannami A, Takamatsu Y, Ito K, Takahashi K (2004) Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 15(3):517–525
Suzuki R, Takizawa T, Kuwata Y, Mutoh M, Ishiguro N, Utoguchi N, Shinohara A, Eriguchi M, Yanagie H, Maruyama K (2008) Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm 346(1–2):143–150. doi:10.1016/j.ijpharm.2007.06.010
Senzer N, Nemunaitis J, Nemunaitis D, Bedell C, Edelman G, Barve M, Nunan R, Pirollo KF, Rait A, Chang EH (2013) Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther 21(5):1096–1103. doi:10.1038/mt.2013.32
Zhou J, Shum KT, Burnett JC, Rossi JJ (2013) Nanoparticle-Based Delivery of RNAi Therapeutics: progress and Challenges. Pharmaceuticals (Basel) 6(1):85–107. doi:10.3390/ph6010085
Aleku M, Schulz P, Keil O, Santel A, Schaeper U, Dieckhoff B, Janke O, Endruschat J, Durieux B, Roder N, Loffler K, Lange C, Fechtner M, Mopert K, Fisch G, Dames S, Arnold W, Jochims K, Giese K, Wiedenmann B, Scholz A, Kaufmann J (2008) Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 68(23):9788–9798. doi:10.1158/0008-5472.can-08-2428
Burnett JC, Rossi JJ, Tiemann K (2011) Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 6(9):1130–1146. doi:10.1002/biot.201100054
Rettig GR, Behlke MA (2012) Progress toward in vivo use of siRNAs-II. Mol Ther 20(3):483–512. doi:10.1038/mt.2011.263
Haussecker D (2012) The Business of RNAi Therapeutics in 2012. Mol Ther Nucleic Acids 1:e8. doi:10.1038/mtna.2011.9
Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6(3):659–668. doi:10.1021/mp900015y
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest statement
The authors declare that there are no conflicts of interests.
Ethical issues
No ethical issues to be promulgated.
Additional information
Elham Ajorlou and Ahmad Yari Khosroushahi have contributed equally.
Rights and permissions
About this article
Cite this article
Ajorlou, E., Khosroushahi, A.Y. Trends on polymer- and lipid-based nanostructures for parenteral drug delivery to tumors. Cancer Chemother Pharmacol 79, 251–265 (2017). https://doi.org/10.1007/s00280-016-3168-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-016-3168-6